I TUOI DATI
I TUOI ORDINI
N. prodotti: 0
Totale ordine: € 0,00
I TUOI ABBONAMENTI
I TUOI ARTICOLI
THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Rivista di Medicina Nucleare e Imaging Molecolare
A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413
ORIGINAL ARTICLES MOLECULAR IMAGING BEYOND NUCLEAR MEDICINE
The Quarterly Journal of Nuclear Medicine and Molecular imaging 2009 December;53(6):671-7
Decreased [99mTc]Sestamibi uptake with dobutamine versus dipyridamole stress
Sciagrà R., Zoccarato O., Bisi G., Pupi A. ✉
1 Nuclear Medicine Unit, Department of Clinical Physiopathology, University of Florence; Florence, Italy;
2 Nuclear Medicine Laboratory, Salvatore Maugeri” Foundation IRCCS, Veruno, Novara, Italy;
3 Nuclear Medicine, University of Turin, Turin, Italy
AIM: Animal studies suggest an interference of dobutamine on [99mTc]sestamibi uptake. In this study dobutamine was compared to dipyridamole rest-stress [99mTc]sestamibi uptake ratio (UR).
METHODS: Twenty-five patients with suspect coronary artery disease (CAD) underwent rest, dobutamine, and dipyridamole [99mTc]sestamibi SPECT at 24-h intervals and coronary angiography. UR was calculated separately for each coronary territory considering injected dose and acquisition delay.
RESULTS: There were 38 CAD territories in 20 patients. On a patient basis, dipyridamole SPECT sensitivity was 85%, versus 70% for dobutamine. On a territory basis, sensitivity was 66% versus 42% (P<0.05), and specificity 92% versus 86%, respectively for dipyridamole versus dobutamine. In the 38 CAD territories, dipyridamole UR was -4.1±29.4%, and dobutamine UR was -13.1±19.9% (P<0.05). In the 37 no-CAD territories, UR was 34±23.6% for dipyridamole and -0.4±17.8% for dobutamine (P<0.0001). UR difference between CAD versus no-CAD territories was larger using dipyridamole (P<0.0001) than dobutamine (P<0.005).
CONCLUSIONS: The UR comparison confirms that [99mTc]sestamibi uptake underestimates the blood flow heterogeneity induced by dobutamine more than that produced by dipyridamole.